fda glp-1 warning letters october 2025 news The has announced that it has given us an expedited review of the once-a-day weight loss pill we're investigating, potentially giving people living with obesity a new treatment option early next September 8, 2025: FDA launches

And while weight management issues are currently plaguing those in uniform, such problems are also thinning the list of prospective recruits amid an historic recruiting crisis

Patients with certain conditions including a personal or family history of medullary thyroid carcinoma, MEN-2, pancreatitis, pregnancy or breastfeeding, among others are not candidates

Some research shows that tirzepatide may help people lose more of their body weight (15% or more of their starting weight) compared with semaglutide

There are potential drawbacks to the short-term program, however

Some foodssuch as carbonated beverages and dairyare also more likely to cause gas

I'm pain free